T Seidal Selected Research

Ovarian Epithelial Carcinoma

3/2012	The apoptosis regulators p53, bax and PUMA: Relationship and impact on outcome in early stage (FIGO I-II) ovarian carcinoma after post-surgical taxane-based treatment.
3/2004	A new prognostic model comprising p53, EGFR, and tumor grade in early stage epithelial ovarian carcinoma and avoiding the problem of inaccurate surgical staging.
5/2002	The prognostic importance of p53, bcl-2, and bax in early stage epithelial ovarian carcinoma treated with adjuvant chemotherapy.
12/2001	Prognostic importance of DNA ploidy and p53 in early stages of epithelial ovarian carcinoma.
3/2001	The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

T Seidal Research Topics

Disease

5	Ovarian Epithelial Carcinoma 03/2012 - 03/2001
4	Neoplasms (Cancer) 03/2004 - 03/2001
2	Carcinoma (Carcinomatosis) 03/2012 - 05/2002
2	Ovarian Neoplasms (Ovarian Cancer) 03/2004 - 12/2001
1	Aneuploidy (Aneuploid) 12/2001
1	Carcinogenesis 03/2001
1	Lung Injury 01/2000

Drug/Important Bio-Agent (IBA)

2	Biological FactorsIBA 03/2004 - 05/2002
2	Biological ProductsIBA 03/2004 - 03/2001
1	taxaneIBA 03/2012
1	PlatinumIBA 03/2012
1	ErbB Receptors (EGF Receptor)IBA 03/2004
1	DNA (Deoxyribonucleic Acid)IBA 12/2001
1	Growth Factor ReceptorsIBA 03/2001
1	ChlorineIBA 01/2000
1	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2000

Therapy/Procedure

2	Drug Therapy (Chemotherapy) 03/2012 - 03/2001
2	Adjuvant Radiotherapy 12/2001 - 03/2001
1	Adjuvant Chemotherapy 05/2002
1	Therapeutics 12/2001